Center-Authored Papers

Filters: First Letter Of Keyword is P  [Clear All Filters]
A B C D E F G H I J K L M N O [P] Q R S T U V W X Y Z   [Show ALL]
Pyrrolidines
LaCroix AZ, Powles T, Osborne KC, Wolter K, Thompson JR, Thompson DD, Allred CD, Armstrong R, Cummings SR, Eastell R et al..  2010.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.. Journal of the National Cancer Institute. 102(22):1706-15. Abstract
Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J et al..  2010.  Lasofoxifene in postmenopausal women with osteoporosis.. The New England journal of medicine. 362(8):686-96. Abstract
LaCroix AZ, Powles T, Osborne KC, Wolter K, Thompson JR, Thompson DD, Allred CD, Armstrong R, Cummings SR, Eastell R et al..  2010.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.. Journal of the National Cancer Institute. 102(22):1706-15. Abstract
Ensrud K, LaCroix AZ, Thompson JR, Thompson DD, Eastell R, Reid DM, Vukicevic S, Cauley J, Barrett-Connor E, Armstrong R et al..  2010.  Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.. Circulation. 122(17):1716-24. Abstract
Pyrroles
Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG.  2010.  Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(21):5260-8. Abstract
Hartwell LH, MAGASANIK B.  1964.  THE MECHANISM OF HISTIDASE INDUCTION AND FORMATION IN BACILLUS SUBTILIS.. Journal of molecular biology. 10:105-19.
Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ.  2008.  An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.. PharmacoEconomics. 26(4):329-39. Abstract
Hansen RN, Hackshaw MD, Sullivan SD, Ramsey SD.  2015.  The Authors Respond.. Journal of managed care & specialty pharmacy. 21(9):844.
Pyrophosphatases
Fishburn J, Hahn S.  2012.  Architecture of the yeast RNA polymerase II open complex and regulation of activity by TFIIF.. Molecular and cellular biology. 32(1):25. Abstract
Pyrimidines
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Turtle CJ, Hay KA, Hanafi L-A, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S et al..  2017.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(26):3010-3020. Abstract
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP et al..  2008.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.. Blood. 112(8):3500-7. Abstract
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC et al..  2011.  Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.. Urology. 77(5):1166-71. Abstract
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond KA, Bramwell VHC, Baker LH, Maki RG et al..  2008.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(4):626-32. Abstract
Radich JP.  2010.  Stem cell transplant for chronic myeloid leukemia in the imatinib era.. Seminars in hematology. 47(4):354-61. Abstract
Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey AE, Flowers MED, Maris MB, Laport GG, Chauncey TR, Lange T et al..  2011.  Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.. Haematologica. 96(8):1113-20. Abstract
Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerema NA, Oehler VG, Wood C et al..  2011.  Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.. Pediatric blood & cancer. 57(1):56-62. Abstract
Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG et al..  2010.  Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).. Blood. 116(19):3758-65. Abstract
Hochhaus A, Müller MC, Radich JP, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim D-W, Lipton JH, Bleickardt E et al..  2009.  Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(9):1628-33. Abstract
Baeten JM, Brown ER, Hillier SL.  2017.  Dapivirine Vaginal Ring for HIV-1 Prevention.. The New England journal of medicine. 376(10):995-6.
Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M et al..  2009.  High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4754-9. Abstract
Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, Gralow JR, Hortobagyi GN, Livingston R.  2008.  A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.. Clinical breast cancer. 8(6):511-5. Abstract
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F et al..  2009.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(35):6041-51. Abstract